Fagron is the global Business-to-Business (B2B) leader in pharmaceutical compounding. It offers raw materials, branded products and concepts and compounding services, thereby bringing personalised pharmaceutical care to healthcare institutions and therefore patients. The company services pharmacies and institutional clients (hospitals and clinics) in 34 countries worldwide.
Traditional medicine is the mainstream approach in most healthcare systems and follows a one-size-fits-all approach. Drugs and other therapies are designed and tested on broad populations and are then prescribed using statistical averages. These drugs are used to treat large groups of people with the same disease, like diabetes or cancer, factoring in some variables such as sex, age, or weight. However, by not considering each person's genetic makeup, traditional medicine can be imprecise, unpredictable, and ineffective. On average, any given prescription drug now on the market only works for half of those who take it (according to the Jackson Laboratory, an independent, non-profit biomedical research institution).
The necessity of having more precise and effective treatments resulted in the development of a scientific field currently known as 'personalised medicine', which tailors health care to each person’s unique genetic makeup. This is done through what is known as drug compounding, the process of combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient. This results in benefits such as reducing side effects, enabling a greater drive towards innovative therapies, and achieving more effective drugs. Fagron is a pure-play in the compounding business and the only listed company active in this field.